Filing Details
Oncotelic Therapeutics, Inc. (OTC:OTLC) filed a Form 8-K with the Securities and Exchange Commission on October 13, 2026, disclosing a material event.
8k filedOTC:OTLC
Oncotelic Therapeutics, Inc. (OTLC) Reports Material Event to SEC
Oncotelic Therapeutics, Inc. (OTC:OTLC) filed a Form 8-K with the Securities and Exchange Commission on October 13, 2026, disclosing a material event.
At publication ·
What changed
Oncotelic Therapeutics, Inc. (OTC:OTLC) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Oncotelic Therapeutics filed a Form 8-K on October 13, 2026, disclosing a material event to shareholders.
- The company's stock trades at $0.02 per share with a market capitalization of $39.8 million.
- Form 8-K filings report material events such as leadership changes, acquisitions, asset sales, or financial guidance changes.
Market Context
Oncotelic Therapeutics, Inc.'s stock currently trades at $0.02 with a market capitalization of $39.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Oncotelic Therapeutics, Inc.'s stock.
All SEC filings for Oncotelic Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View OTLC Stock Page
Frequently Asked Questions
Where can I read OTLC's SEC filings?
Browse all filings on our OTLC SEC filings page.
What types of SEC filings does Oncotelic Therapeutics, Inc. file?
Public companies like Oncotelic Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.